Mass General Brigham Ventures LLC

11/17/2026 | Press release | Distributed by Public on 11/17/2026 19:43

Dual-targeted CAR T-cell therapy shows promise in patients with treatment-resistant multiple myeloma

Dual-targeted CAR T-cell therapy shows promise in patients with treatment-resistant multiple myeloma

Published November 17, 2026

In a phase 1 trial led by Mass General Brigham Cancer Institute researchers, the new treatment reduced or eliminated signs of cancer in 80% of the 15 treated patients

A first-in-human study by Mass General Brigham Cancer Institute Open external link in a new window investigators found that a chimeric antigen receptor (CAR) T-cell therapy called TriPRIL reduced or eliminated signs of cancer in 12 of 15 patients with relapsed or refractory multiple myeloma. TriPRIL - short for trimeric APRIL (a proliferation-inducing ligand) - recognizes two proteins on myeloma cells instead of just one. Researchers published their findings in The Lancet Open external link in a new window .

Multiple myeloma is a cancer of plasma cells, which are immune cells that make antibodies. To create CAR T-cell therapy, scientists modify a patient's T cells so they can find and attack myeloma cells. Existing CAR T-cell therapies recognize B-cell maturation antigen (BCMA) on myeloma cells. TriPRIL was engineered by Mass General Brigham researchers to make the CAR-T cells recognize both BCMA and a second protein, transmembrane activator and CAML interactor (TACI). Because the treatment is based on human proteins, the researchers believe it may be less likely to lead to anti-drug antibodies that can reduce the long-term persistence and effects of other CAR-T cells.

"BCMA-targeted CAR T-cell therapy has transformed multiple myeloma treatment, but most patients eventually relapse," said co-senior author Marcela V. Maus, MD, PhD Open external link in a new window , director of the Mass General Brigham Cancer Institute's Cellular Immunotherapy Program. " TriPRIL adds TACI as a second target, allowing it to find and attack myeloma cells, even if they stop expressing BCMA."

The phase 1 TriPRIL trial treated 15 patients at the Mass General Brigham Cancer Institute whose multiple myeloma had come back despite many treatments. Nine patients had previously received BCMA-directed CAR T-cell therapy but saw their cancer progress. Twelve of the fifteen patients (80%) responded, meaning cancer signs fell by at least half. In eight (53%), blood, urine and bone marrow tests found no signs of active myeloma.

TriPRIL cells remained detectable in some patients' blood beyond six months after treatment. The treatment was also relatively safe, with no severe cases of cytokine release syndrome or neurotoxicity.

"Seeing this new treatment work in patients whose cancer had returned after treatment targeting BCMA stood out," Maus said. "It was also encouraging that the patients we tested showed no immune reaction against TriPRIL.

Because the study included only 15 patients and followed them for a relatively short time, researchers need larger, longer studies to determine how long the benefits last and identify less common side effects. They are planning a phase 2 trial with more patients and longer follow-up.

Authorship: In addition to Maus, Mass General Brigham authors include Benjamin R. Puliafito, Charlotte E. Graham, Noopur S. Raje, Andrew J. Yee, Diana D. Cirstea, Andrew R. Branagan, Nora K. Horick, Aiyana L. Parker, Maxx King, Marisa G. Ogier, Mark B. Leick, Kathleen M.E. Gallagher, and Matthew J. Frigault. Additional authors include Sarah Nikiforow and members of the TriPRIL Working Group.

Disclosures: Maus is an inventor on patents related to this study and adoptive cell therapies held by Massachusetts General Hospital and the University of Pennsylvania, some of which are licensed to biotechnology companies. She receives research support from BMS, Kite Pharma and Sobi; serves as a consultant to multiple cell therapy companies; holds equity in A2Bio, Altido Therapeutics, Caronilex and Umoja; and serves on the board of directors of Umoja. Additional author disclosures can be found in the paper.

Funding: This research was funded by internal Mass General Brigham funding. Additional support for correlative studies was provided by the V Foundation.

Paper cited: Puliafito BR., et al. "Trimeric APRIL (TriPRIL) CAR T-cell therapy for relapsed or refractory multiple myeloma: A first-in-human phase 1 trial using a dual-targeted, ligand-based CAR." The Lancet. DOI: 10.1016/S0140-6736(26)01806-4

Media contact

Alex Pantano
Senior Specialist, External Communications
[email protected]

About Mass General Brigham

Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation's leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.

Mass General Brigham Ventures LLC published this content on November 17, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 18, 2026 at 01:44 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]